Multilocular clear cell renal cell carcinoma is a rare kidney tumor made up of many fluid-filled spaces. It often causes no symptoms at first, and many people learn they have multilocular clear cell renal cell carcinoma after a scan done for another reason. When symptoms do happen, they can include blood in the urine, side or back pain, or a lump in the abdomen, which can be early symptoms of kidney cancer. It is most often found in adults, and treatment usually involves surgery to remove part or all of the kidney. This tumor usually grows slowly and has a very low risk of spreading, so the outlook is often excellent after treatment.
How many people live with Multilocular clear cell renal cell carcinoma?
This rare type of kidney cancer is not usually counted on its own: about 1.7 million people worldwide were living with kidney cancer within 5 years of diagnosis (Global Cancer Observatory, 2022), so if this subtype makes up about 1% to 2% of kidney tumors, depending on how tumors are classified, that suggests roughly 17,000 to 34,000 people worldwide are living with it, but this is an estimate rather than a direct count. In the United States, about 599,000 people were living with kidney cancer or cancer in the part of the kidney that drains urine on January 1, 2021 (NCI SEER, 2024), which suggests roughly 6,000 to 12,000 people with this subtype, again as an estimate rather than a direct count.
Overview
Multilocular clear cell renal cell carcinomaSymptoms
Multilocular clear cell renal cell carcinoma often causes no symptoms at first and may be found during imaging for something else. When symptoms do happen, they can include blood in the urine, side or back pain, a belly mass, fatigue, or unexplained weight loss.
Outlook and prognosis
Multilocular clear cell renal cell carcinoma usually has an excellent outlook. After surgery, most people do very well because this tumor tends to grow slowly and is unlikely to spread. Follow-up scans help check that it does not come back.
Causes and risk factors
Multilocular clear cell renal cell carcinoma usually develops from acquired DNA changes in kidney cells; rarely, inherited kidney cancer syndromes raise risk. Smoking, obesity, high blood pressure, and long-term kidney disease can also increase the chance of developing it.
Genetic influences
Genetics are important in multilocular clear cell renal cell carcinoma, but many cases are not strongly inherited. Changes affecting the VHL pathway may play a role, and family history can matter, especially when kidney tumors run in families.
Diagnosis
Multilocular clear cell renal cell carcinoma is usually found with imaging such as ultrasound, CT, or MRI, often after a kidney mass is seen. Diagnosis is confirmed by pathology after biopsy or surgery.
Treatment and drugs
Treatment for multilocular clear cell renal cell carcinoma usually involves surgery to remove the tumor, often while saving the rest of the kidney. Small tumors may be watched closely. Follow-up scans help check for recurrence.
Symptoms
Many people with multilocular clear cell renal cell carcinoma feel well at first, and the tumor is sometimes found during a scan done for another reason. When symptoms do happen, they are usually similar to those of other kidney cancers and can affect urination, energy, or comfort in the side or back. You might notice small changes at first, especially because the early symptoms of multilocular clear cell renal cell carcinoma can be vague. Symptoms vary from person to person and can change over time.
Multilocular clear cell renal cell carcinoma often causes no clear symptoms when it is small. Many people learn they have it only after an ultrasound or CT scan for belly pain, a kidney stone, or another unrelated issue.
Urine may look pink, red, or cola-colored, or the bleeding may be too small to see without a test. Even one episode of blood in the urine should be checked, because it can also happen with infections, stones, or other kidney problems.
Some people feel a dull ache or pressure in the side, lower back, or area near one kidney. This pain is often persistent rather than coming and going like a muscle strain.
A larger kidney tumor can cause a feeling of fullness, swelling, or a lump in the belly or side. For many, this can mean clothes feel tighter on one side or lying in certain positions becomes uncomfortable.
How people usually first notice Multilocular clear cell renal cell carcinoma?
Many people with multilocular clear cell renal cell carcinoma do not feel anything at first, and it is often first noticed by chance during an ultrasound, CT scan, or MRI done for another reason. When symptoms do appear, the first signs of multilocular clear cell renal cell carcinoma are usually blood in the urine, aching pain in the side or lower back, or less often a lump in the abdomen. Some may also notice tiredness, unexplained weight loss, or fever, but these symptoms are not specific, which is why imaging and follow-up testing are so important.
Types of Multilocular clear cell renal cell carcinoma
Multilocular clear cell renal cell carcinoma is already a specific, uncommon subtype of kidney cancer rather than a broad condition with several well-established forms. In everyday life, many people have no symptoms at first, and when symptoms do appear they usually depend more on the tumor’s size and location than on a separate variant. Researchers and doctors do not generally divide this diagnosis into additional accepted subtypes, so discussions about variants of multilocular clear cell renal cell carcinoma are limited.
No distinct subtypes
Multilocular clear cell renal cell carcinoma is itself a recognized subtype of renal cell carcinoma. No widely accepted further types of multilocular clear cell renal cell carcinoma are used in routine medical care.
Can I slow down the onset of symptoms?
No, there is no good evidence that lifestyle changes or medicines can meaningfully delay the start of symptoms for this type of kidney cancer once it is already present. Healthy habits such as not smoking, staying active, keeping a healthy weight, controlling blood pressure, and sleeping well are good for your kidneys and may lower the risk of kidney cancer in general, but they are not proven to prevent this tumor or stop symptoms from appearing. There is no proven preventive medication, but regular follow-up with scans when your care team recommends them can catch changes early; research is still ongoing, so the best approach is careful monitoring and timely treatment if needed.
What genetics can tell you about symptoms
In multilocular clear cell renal cell carcinoma, genetics can show that the tumor is closely related to the usual clear cell type of kidney cancer, and some tumors have changes in the VHL gene or nearby chromosome material. But for most people, these genetic changes do not clearly predict which symptoms will show up, how severe they will be, or exactly when they will start; symptoms are more often linked to the tumor’s size and location, and many are found before causing any symptoms at all. Researchers are still studying whether certain genetic patterns affect behavior in a meaningful way, but this tumor type is generally known for a more indolent course than typical clear cell kidney cancer.
Causes and risk factors
Multilocular clear cell renal cell carcinoma usually starts when kidney cells collect DNA changes and begin growing in an abnormal way. Most cases are not inherited, but some are linked to gene changes passed through families, especially changes involving the VHL gene. Older age, being male, long-term kidney disease, and rare inherited kidney cancer syndromes can raise the risk of multilocular clear cell renal cell carcinoma. Smoking, obesity, high blood pressure, and some workplace chemical exposures can also increase risk. It’s rarely just one factor—it’s the mix that matters.
What are the most common causes or risk factors?
The exact cause of multilocular clear cell renal cell carcinoma, a rare type of kidney cancer, is often not clear, but many cases are linked to changes in genes that control how kidney cells grow; changes in a gene called VHL are especially common, and a rare inherited condition called von Hippel-Lindau syndrome can raise risk. The most important non-genetic risk factors are smoking, carrying extra body weight, and high blood pressure. Risk also tends to be higher in older adults and in people with a close family history of kidney cancer.
Environmental and biological risk factors
Because it is rare, specific risk factors for multilocular clear cell renal cell carcinoma are not as well studied as risk factors for clear cell kidney cancer overall. Many people who develop this tumor do not have one obvious cause. Doctors often group risks into internal (biological) and external (environmental). For this condition, the main non-genetic risks involve age, sex, kidney health, and certain chemical exposures.
Multilocular clear cell renal cell carcinoma is usually found in adults rather than children. Risk rises with age because kidney cells have had more time to accumulate damage.
Kidney cancers are diagnosed more often in men than in women. The reasons are not fully clear, but underlying biological differences may play a part.
Long-standing high blood pressure is linked with a higher chance of kidney cancer, including clear cell forms. Ongoing strain on kidney tissue and blood vessels may help explain this link.
Reduced kidney function over many years can raise the risk of kidney tumors. This is especially true for people with advanced kidney disease, years of dialysis, or acquired cystic changes in the kidneys.
Genetic risk factors
For many people, the main genetic story behind multilocular clear cell renal cell carcinoma is a change in how kidney cells control growth. Some risk factors are inherited through our genes. Most genetic changes linked to this tumor arise only in the kidney cells that form the tumor, while a smaller number are passed down in families. When doctors look into the genetic causes of multilocular clear cell renal cell carcinoma, they mainly focus on VHL-related changes and loss of part of chromosome 3.
VHL gene: Changes in the VHL gene are the most common genetic finding in multilocular clear cell renal cell carcinoma. VHL normally helps keep cell growth and oxygen-sensing signals under control. When it stops working properly, abnormal kidney cells can survive and multiply.
Chromosome 3p loss: Many clear cell kidney tumors lose a small piece of chromosome 3, often called 3p. That missing segment contains VHL and other genes that help suppress tumors. Losing this region can be an early step toward tumor formation.
Inherited VHL syndrome: A small number of people inherit a harmful VHL gene change, causing von Hippel-Lindau syndrome. This inherited condition raises the risk of clear cell kidney cancers, sometimes at a younger age or in both kidneys. Not everyone with the same gene change develops the same pattern of tumors.
Family history: Having close relatives with clear cell kidney cancer can point to an inherited risk, even when the exact gene is not known. This matters more when several family members are affected or when kidney tumors show up at a young age.
Chromosome 3 translocation: Very rarely, families carry an inherited rearrangement involving chromosome 3, sometimes called a translocation. This can increase the risk of clear cell kidney cancers by disrupting genes that normally protect against tumor growth.
Lifestyle risk factors
Several everyday habits can influence the chance of developing renal cell carcinoma and may also affect outcomes after treatment. For multilocular clear cell renal cell carcinoma, the strongest lifestyle-related influences are tobacco exposure, excess body weight, low physical activity, and patterns that worsen blood pressure or metabolic health. When people ask about lifestyle risk factors for multilocular clear cell renal cell carcinoma, the most useful focus is on habits that strain the kidneys, promote chronic inflammation, or increase carcinogenic exposure.
Smoking is one of the clearest modifiable risks for renal cell carcinoma because tobacco chemicals enter the bloodstream and are filtered through the kidneys. Heavier or longer-term smoking is linked to higher risk, while quitting can gradually lower that risk over time.
Overweight and obesity raise renal cell carcinoma risk through chronic inflammation, insulin resistance, and hormone signaling changes that can support tumor development. Weight control may be especially important because obesity is a consistent lifestyle factor linked to clear cell kidney cancers.
Physical inactivity can worsen weight gain, insulin resistance, and blood pressure, which are all tied to kidney cancer risk. Regular exercise may help lower these drivers and improve recovery, energy, and overall health during or after treatment.
Diets high in calorie-dense ultra-processed foods and low in vegetables, fruits, and fiber can promote obesity and metabolic dysfunction that raise kidney cancer risk. A balanced eating pattern supports healthier weight and blood pressure, which may reduce how lifestyle affects multilocular clear cell renal cell carcinoma risk.
Risk prevention
There is no sure way to prevent multilocular clear cell renal cell carcinoma, but many of the same steps that lower the risk of kidney cancer are still worth taking. For many, this means focusing on everyday habits that protect the kidneys and overall health over time. Prevention is about lowering risk, not eliminating it completely. If kidney cancer runs in your family or you have certain inherited conditions, regular medical follow-up may help find problems earlier.
Smoking raises the risk of kidney cancers, including multilocular clear cell renal cell carcinoma. Quitting can help lower that risk over time, even if you have smoked for years.
Carrying extra body weight increases the risk of renal cell carcinoma. Steady habits such as regular movement and balanced meals can help lower risk and support blood pressure control too.
High blood pressure is linked with a higher chance of kidney cancer. Keeping it in a healthy range with lifestyle changes and medicines when needed may help protect the kidneys.
Long-term exposure to some industrial chemicals may raise kidney cancer risk in certain jobs. Using protective equipment and following workplace safety rules can reduce avoidable exposure.
Can you prevent Multilocular clear cell renal cell carcinoma?
There is no sure way to prevent multilocular clear cell renal cell carcinoma, which is a rare type of kidney cancer. But some well-known steps may help lower the risk of kidney cancer in general, including not smoking, staying at a healthy weight, and treating high blood pressure if you have it. Even when people do these things, this cancer can still happen, so prevention is not always possible.
Transmission
Multilocular clear cell renal cell carcinoma is not contagious, so it cannot be transferred from one person to another through touch, kissing, sex, coughing, blood, or everyday contact. Even if the cancer spreads to other parts of the body, that is spread within the same person, not an infection that someone else can catch.
Many living with this kidney cancer also wonder about how multilocular clear cell renal cell carcinoma is inherited. In most cases, it is not passed down in families and happens sporadically, although a small number of kidney cancers can be linked to inherited gene changes that raise risk.
When to test your genes
Consider genetic testing if this kidney cancer appears at a young age, if you have more than one kidney tumor, tumors in both kidneys, or a family history of kidney cancer. Tumor gene testing is most useful when treatment choices are unclear, especially in advanced disease, because it can help tailor care.
Diagnosis
Multilocular clear cell renal cell carcinoma is usually found after imaging shows a kidney mass, sometimes during a scan done for another reason and sometimes after symptoms like blood in the urine, side or back pain, or an unexpected kidney finding. Because this tumor can resemble other cystic kidney growths, doctors often combine scan results, pathology, and sometimes surgery to confirm the diagnosis of multilocular clear cell renal cell carcinoma. For some, routine check-ups reveal the first clues.
Doctors ask about symptoms, smoking history, kidney problems, and any family history of kidney cancer or inherited conditions. A detailed family and health history can help decide whether genetic counseling or added testing is needed.
A physical exam helps look for signs of kidney disease, high blood pressure, or related health issues. The exam alone cannot confirm this cancer, but it helps guide the rest of the workup.
Urine tests may look for blood or other abnormalities, while blood tests check kidney function, blood counts, and general health. These results do not diagnose the tumor by themselves, but they help rule out common conditions and prepare for treatment.
Ultrasound, CT, and MRI are the main tests used to study a kidney mass and see whether it looks cystic, solid, or mixed. In the diagnosis of multilocular clear cell renal cell carcinoma, imaging helps estimate how likely the mass is to be cancer and whether it has spread.
How is Multilocular clear cell renal cell carcinoma diagnosed?
Doctors usually find this rare kidney tumor after imaging tests such as an ultrasound, CT scan, or MRI show a cyst-like growth in the kidney. Because scans alone often cannot tell exactly what kind of growth it is, the diagnosis is usually confirmed by examining tissue under a microscope, often after surgery or sometimes from a biopsy, which is a small tissue sample. Genetic testing is not usually needed to make the diagnosis, but it may be offered if someone is young, has a strong family history of kidney cancer, or has other signs that suggest an inherited condition.
Stages of Multilocular clear cell renal cell carcinoma
Multilocular clear cell renal cell carcinoma does not have defined progression stages. This is because it is usually identified as a specific cystic kidney tumor on scans and then confirmed under the microscope, rather than being tracked through a typical step-by-step decline over time. Doctors usually start with a conversation about symptoms, but many living with multilocular clear cell renal cell carcinoma have no early symptoms of multilocular clear cell renal cell carcinoma and find out after an ultrasound, CT scan, or MRI done for another reason. Diagnosis and follow-up usually rely on imaging, surgery or biopsy findings when needed, and pathology results to confirm that the tumor has low malignant potential.
Outlook and prognosis
The outlook for multilocular clear cell renal cell carcinoma is overwhelmingly favorable, especially when the tumor is completely removed. In modern series, these tumors behave in an indolent way, with extremely low risk of recurrence or metastasis compared with conventional clear cell renal cell carcinoma. Cancer-specific survival is considered excellent, and many experts now classify this entity as a lesion of very low malignant potential. Reported deaths directly attributable to this tumor are exceedingly rare, and mortality after appropriate surgical treatment is essentially near zero in most published experience. Prognosis may also be aided by the fact that these tumors are often detected at an early, localized stage, allowing curative management with partial or total nephrectomy depending on the case.
Long-term effects
Many people with multilocular clear cell renal cell carcinoma have an excellent outlook, especially when the tumor is found before it has spread. This kidney tumor subtype usually behaves much less aggressively than most other kidney cancers, and many people have no early symptoms of multilocular clear cell renal cell carcinoma before it is picked up on a scan for something else. The long-term picture is often very favorable after treatment, although follow-up is still important to confirm that the cancer does not return.
Long-term survival is usually excellent when multilocular clear cell renal cell carcinoma is fully removed. In most reported cases, people remain cancer-free for years after surgery.
The risk of the cancer coming back is very low compared with more typical clear cell kidney cancers. Even so, doctors usually monitor over time because no cancer diagnosis is treated as completely risk-free.
Spread to other parts of the body is rare in multilocular clear cell renal cell carcinoma. This very low metastatic potential is one reason the prognosis is generally so good.
Long-term effects can sometimes relate more to treatment than to the tumor itself, especially if part or all of a kidney was removed. Some may have little change in daily life, while others can have reduced kidney function that needs monitoring over the years.
How is it to live with Multilocular clear cell renal cell carcinoma?
Living with multilocular clear cell renal cell carcinoma can feel strangely uneven, because some people have no symptoms at first and learn about it after imaging for something else, while others live with worry, follow-up scans, surgery, and the disruption that comes with a cancer diagnosis. In daily life, the biggest effects often come from treatment and monitoring rather than from the tumor itself, which can mean time away from work, limits during recovery, fatigue, and the mental strain of waiting for results, even though this subtype is often less aggressive than many other kidney cancers. The people around you may take on practical roles such as driving to appointments, helping during recovery, or carrying some of the emotional weight, so the condition often touches the whole household, not just the person receiving care.
Treatment and drugs
Treatment for multilocular clear cell renal cell carcinoma usually focuses on removing the tumor, because this type of kidney cancer is often found as a small, localized growth and surgery can be very effective. Depending on the tumor size and where it sits in the kidney, doctors may remove just the tumor or part of the kidney, while some people need the whole kidney removed. Not every treatment works the same way for every person, and in rare cases where multilocular clear cell renal cell carcinoma has spread or cannot be fully removed, care may include targeted cancer drugs, immunotherapy, or careful monitoring after treatment. Follow-up scans and checkups matter because even after successful treatment, your team will watch for signs that the cancer has come back and help guide recovery after kidney surgery.
Can you cure Multilocular clear cell renal cell carcinoma?
There is no guaranteed cure for multilocular clear cell renal cell carcinoma, but many people can be cured if it is found early and removed with surgery. This is a rare type of kidney cancer that often has a very good outlook when it has not spread. If it has spread or cannot be fully removed, treatment can still help control the cancer, slow its growth, and manage symptoms.
Non-drug treatment
For many living with multilocular clear cell renal cell carcinoma, care often centers on removing or closely watching the tumor rather than using medicine. This kidney tumor is often found by chance on a scan, and treatment choices depend on the size of the mass, where it sits in the kidney, your overall health, and whether it seems to be growing. Managing this condition often means balancing cancer control with protecting as much kidney function as possible, so treatment options for multilocular clear cell renal cell carcinoma can look different from one person to the next.
Small tumors that look low risk on imaging can sometimes be watched with regular scans instead of treated right away. This may suit older adults, people with other major health problems, or those with a very small mass that is not changing much.
This surgery removes the tumor while leaving the rest of the kidney in place. It is often the preferred option when possible because it treats the cancer and helps preserve kidney function.
If the mass is large, in a difficult position, or taking up much of the kidney, the whole kidney may need to be removed. Many people do well with one healthy kidney, but kidney function is followed closely afterward.
Some small tumors can be treated by heating or freezing them with a needle placed through the skin, usually guided by imaging. This is less invasive than standard surgery and may help people who are not good candidates for an operation.
Your genes may have an impact on how drugs work for you
For many living with multilocular clear cell kidney cancer, surgery is the main treatment, so genetic differences usually do not play as big a role in day-to-day medication choices as they do in some other cancers. If the cancer has spread or comes back and drug treatment is needed, changes in the tumor itself can sometimes help doctors predict whether targeted cancer drugs or immune-based treatments are more likely to help. This is one reason some people have testing on the cancer tissue, but for this specific type of kidney cancer, gene-based drug matching is not yet a routine part of care for everyone.
Pharmacological treatments
For most people with multilocular clear cell renal cell carcinoma, medicine is not the main treatment because this tumor is usually slow-growing and often cured with surgery alone. Drug treatment is mainly considered only in the very rare situation where the cancer has spread, comes back, or behaves more like advanced clear cell kidney cancer. In that setting, doctors often use the same systemic medicines used for other clear cell renal cancers. Finding the right medication can be a process of trial, patience, and adjustment.
There is no standard drug treatment for localized multilocular clear cell renal cell carcinoma. In most cases, medicines are not needed after the tumor is removed because the risk of spread is very low.
Nivolumab, pembrolizumab, and ipilimumab help the immune system recognize and attack kidney cancer cells. These medicines may be used in rare advanced cases, including when doctors are treating it like metastatic clear cell renal cancer.
Axitinib, cabozantinib, lenvatinib, pazopanib, and sunitinib block growth signals and blood supply that kidney cancers use. Some medicines work quickly, while others are used after another treatment stops helping.
Pembrolizumab with axitinib or lenvatinib, and nivolumab with cabozantinib, are common combinations for advanced clear cell kidney cancer. In some cases, medicines are combined for a stronger effect than either drug alone.
Genetic influences
Most people with multilocular clear cell renal cell carcinoma develop it by chance rather than because of a gene change they were born with. Even so, genetics can still play a part, because many of these tumors have changes in the VHL gene that develop in the kidney cells themselves over time. Family history is one of the strongest clues to a genetic influence. Rarely, multilocular clear cell renal cell carcinoma or other clear cell kidney tumors can be linked to an inherited condition such as von Hippel-Lindau syndrome, especially when kidney cancer appears at a younger age, in both kidneys, or in several relatives. If that pattern is present, genetic counseling and sometimes genetic testing for kidney cancer may help clarify whether the risk runs in the family. A gene change found in the tumor does not always mean it was inherited, which is why doctors look at both the tumor results and your family history together.
Is Multilocular clear cell renal cell carcinoma genetic?
Genetics are important in multilocular clear cell renal cell carcinoma, but many cases are not strongly inherited. Changes affecting the VHL pathway may play a role, and family history can matter, especially when kidney tumors run in families.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a usual part of being human, and they are common across the population. Most do not directly affect health and simply reflect normal human variation. In many genes, having a variant associated with a condition points to a possible link, not a certain diagnosis, particularly when more than one gene and environmental influences play a role. In other situations, though, one well-understood variant in a particular gene is enough to establish the diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with multilocular clear cell renal cell carcinoma, treatment is usually shaped more by the tumor itself than by how someone processes medicine. This type of kidney tumor usually behaves in a very low-risk way, so surgery alone, often a kidney-sparing operation, is the main treatment and drug therapy is not commonly needed. Some tumors have gene changes in pathways also seen in other clear cell kidney cancers, but for this condition those findings do not usually lead to a different standard medicine.
Genetic testing for multilocular clear cell renal cell carcinoma may still matter when there is a strong family history of kidney cancer, several kidney tumors, tumors in both kidneys, or diagnosis at a young age, because that can suggest an inherited condition and change follow-up for you and relatives. Genetics is only one factor, and if the diagnosis is uncertain or the cancer acts more like another kidney cancer, doctors may combine tumor genetics with your overall health to decide whether targeted drugs or immunotherapy make sense. In most cases, though, the key decisions are confirming the diagnosis and choosing the safest surgery rather than matching a drug to a gene result.
Interactions with other conditions
For many living with multilocular clear cell renal cell carcinoma, the biggest day-to-day issue is often not the tumor alone but how it fits into overall kidney health. If someone already has chronic kidney disease, high blood pressure, diabetes, or only one working kidney, treatment decisions may need extra care because protecting kidney function becomes a major priority. Another important aspect is how it may link with other diseases. Some kidney tumors can occur as part of inherited conditions such as von Hippel-Lindau syndrome, so a strong family history of kidney tumors or certain cysts can sometimes lead doctors to consider genetic evaluation. Multilocular clear cell renal cell carcinoma is usually a slow-growing form of kidney cancer, but it can still be harder to sort out when other kidney problems, kidney cysts, or another kidney mass are present on imaging. Interactions can look very different from person to person, and the best plan often depends on tumor size, the health of the other kidney, and whether there are other long-term conditions that raise surgical or anesthesia risk.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Multilocular clear cell renal cell carcinoma?
Other kidney problems can look similar to multilocular clear cell renal cell carcinoma, especially complex kidney cysts, other kinds of kidney cancer, and some noncancerous kidney growths. Kidney stones or a kidney infection can also cause signs like blood in the urine or pain in the side, so they may be considered at first. Because this tumor often shows up as a cyst-like mass on a scan, doctors usually need careful imaging and sometimes tissue testing to tell these apart.
History
People living with a kidney mass often want to know how doctors came to understand it, especially when the name sounds long and unsettling. Multilocular clear cell renal cell carcinoma has gone through important changes in how it was described, named, and classified, and that history helps explain why many cases today are approached differently from other kidney cancers.
When pathologists first reported these tumors, they focused on what they could see under the microscope and in the removed kidney tissue: a growth made up of many fluid-filled spaces, lined by cells that looked similar to clear cell kidney cancer cells. Because of that appearance, the condition was originally grouped with renal cell carcinoma. At the time, doctors knew it behaved differently in many patients, but early classifications were based more on structure than on long-term follow-up.
As medical science evolved, more reports showed a consistent pattern. Many living with multilocular clear cell renal cell carcinoma had tumors that appeared less aggressive than typical clear cell kidney cancer, especially when the growth was made up almost entirely of cysts rather than a solid mass. For families, this could mean hearing that a kidney tumor looked worrisome on a scan, then later learning after surgery that it had a very low risk of spreading.
Over time, longer follow-up studies gave doctors more confidence that this tumor type usually has an excellent outlook when it meets strict pathologic criteria. That led experts to refine the diagnosis and, in modern classification systems, many tumors once called multilocular clear cell renal cell carcinoma are now placed in a separate category called multilocular cystic renal neoplasm of low malignant potential. The older name is still seen in medical records and older articles, so some may come across both terms when reading about the condition.
This shift mattered because names shape expectations. A label containing “carcinoma” naturally sounds alarming, but the updated terminology reflects what years of observation showed: when the tumor has the typical cystic pattern and lacks more aggressive features, it behaves much more gently than most other kidney cancers. Knowing this history can make the diagnosis less confusing and helps explain why the early symptoms of multilocular clear cell renal cell carcinoma, imaging findings, and final pathology report all play a role in deciding what the diagnosis truly means.